Clinical Trial Search

Primary: The Serum Biomarkers of Inflammatory Cytokines

Primary: Annualized Asthma Exacerbation Rate (AER) Through Week 52 — 0.72; 0.27; 0.20; 0.23 events per person-year — p=<0.001

Primary: Primary Effectiveness Endpoint Success Number of Successes (Subjects That Had no Inter-operative CSF Leak Following Valsalva Maneuver and no CSF Leak or…

Primary: Number of Participants With Wound Closure — 8 participants

Primary: Immunological Responses — 8.33; 11.24 cells/mm^3 — p=0.56

Primary: Percentage of Participants Who Experience at Least 1 Adverse Event (AE) — 72.8; 76.2 Percentage of Participants

Primary: Pre-Intervention Pain Tolerance — 46.49; 47.06; 46.16; 46.82 celcius

Primary: Change in Left Ventricular End-diastolic Volume (LVEDV) — 11.873; -0.954 ML — p=<0.0001

Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Evacetrapib — 983; 1170; 1120 nangram/milliliter (ng/mL)

Primary: Change From Baseline in Plasma HIV-1 RNA at 168 Hours Post-Dose — -1.67; -1.35; -1.60; -1.30 log10 copies/mL

Primary: Number of Patients That Experience Pulmonary Complications After Admission From the Emergency Department — 171; 38 participants

Primary: Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 24 — 44.3 percentage of participants

Primary: Area Under the Concentration Time-curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-8892 at Day 1 and Day 28 — 0.143; 0.123; 0.192; 0.863 μM*hr

Primary: Percentage of Participants With Disease Activity Score Based on 28-Joints Count (DAS28) Less Than (<) 2.6 at Month 6 and Maintained Till Month 12 — 43.4; 30.0 percentage…

Primary: Number of Participants With a Decrease in the Number of Apnea and/or Hypopnea Events to <5 Per Hour of Sleep — 5; 3 Participants — p==0.946